Genmab A/S will lose its lucrative royalty stream from the multiple myeloma blockbuster Darzalex sooner than it had hoped after it lost to Johnson & Johnson on two matters at arbitration, raising concerns for the firm’s future finances.
Darzalex (daratumumab), an anti-CD38 monoclonal antibody (mAB), was developed under a years old agreement between the firms under which Genmab...